Dr. Nimer on the Biggest Challenges of MDS

Stephen D. Nimer, MD, Director, Professor of Medicine, Sylvester Comprehensive Cancer Center discusses the challenges of treating myelodysplastic syndromes (MDS).

Patients with MDS have a wide variety of survival outcome; some may live for years while others only for months. Understanding from the beginning the expected progression of each individual patient it is critical, says Nimer.

Although there are three FDA approved drugs for MDS, none are curative and when patients progress on these drugs the prognosis is poor. New drug are needed as well as additional understanding on how stem-cell transplantation and drug therapies can be combined, says Nimer.